Far more MOUNJARO-taken care of patients who produced anti-tirzepatide antibodies knowledgeable hypersensitivity reactions or injection site reactions than individuals that did not develop these antibodies [see ADVERSE REACTIONS ].Tirzepatide is often a GIP receptor and GLP-one receptor agonist. It's a 39-amino-acid modified peptide which has a C20